Abstract: The polymerase gene mutant contained a combination of three mutations (rtV173L, rtL180M, rtM204V), two of which resulted in changes to the overlapping viral envelope of the hepatitis B surface antigen (sE164D, sI195M).
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
PMID: 19301976
2009
The Journal of infectious diseases
Abstract: UDPS detected drug-resistance mutations that were not detected by PCR in 10 samples from 5 NRTI-treated patients, including the lamivudine-resistance mutation V173L (in 5 samples), the entecavir-resistance mutations T184S (in 2 samples) and S202G (in 1 sample), the adefovir-resistance mutation N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations V173L, L180M, A181T, and M204V (in 1 sample).
Method: Established NRTI-resistance mutations included the following RT mutations: rtL80V/I, rtI169T, PMID: 19475624
2009
Journal of medical virology
Abstract: In this latter group, the prevalence of the rtV173L + rtL180M + rtM204V triple mutation was 31% versus a prevalence of 3.4% observed among patients infected with HBV only.
New approaches in the management of chronic hepatitis B: role of tenofovir.
Method: The other patient presented with mutations in the HBV polymerase of rtM204V, rtL180M, rtV173L, and rtA194T, but there was a progressive decline in both HBV DNA and alanine aminotransferase (ALT) levels.
Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.
Abstract: RESULTS: The mutations rtF166L/sF158Y (lamivudine-associated, compensatory) and rtl169T/sF161L (entecavir-associated, primary) acting alone, and the mutations rtV173L/sE164D (lamivudine-associated, compensatory) and rtSilent/sD144E (antibody escape-associated) each when combined with rtM204V/sl195M (lamivudine-associated, primary) led to decreases in antibody reactivity to epitopes in the first or second loop, or in both loops.
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Abstract: The rtV173L+L180M+M204V dominant mutant displayed strong lamivudine-resistance and the highest replication capacity.
Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
PMID: 17506609
2007
AIDS research and human retroviruses
Abstract: Additionally, two of them exhibited the additional rtV173L mutation.
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
PMID: 17567633
2007
The Journal of antimicrobial chemotherapy
Abstract: All but three patients had baseline rtM204I/V substitutions associated with rtL180M in 23, rtL80I/V in 14, rtV173L in 4, rtT184S in 3, rtQ215S in 2 and rtA181S in 2 cases.
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.
PMID: 17913933
2007
Journal of clinical microbiology
Abstract: After 36 months, a compensatory mutation was seen at position rt173 (V173L) in 3/15 patients.
HBV mutation literature information.
PMID: 
2009
Hepatology (Baltimore, Md.)
Browser Board
Co-occurred Entities
Filtrator
ViMRT